Select A Category


A Phase II Clinical Trial of Pembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with Metastatic-Triple-Negative Breast Cancer

Protocol Chair: Leisha A. Emens, MD, PhD

Protocol Officer: Samuel Jacobs, MD

Primary Objective: To establish the recommended biologic dose of AE37 in combination with pembrolizumab that will enhance the tumor-specific immune response and demonstrate efficacy in patients with advanced triple-negative breast cancer.

Patient Population: Metastatic triple-negative breast cancer

Target Accrual: 29 patients

Status: Recruiting participants

ClinicalTrials.gov Identifier: NCT04024800